Email: cspc@cspc.cn
Media
News Center
Sep. 24
2026
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR THE TREATMENT OF ADVANCED BREAST CANCER OFFICIALLY INI
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF BECOTATUG (JMT101) IN COMBINATION WITH OSIMERTINIB FOR THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR META
Sep. 16
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2069 INJECTION FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN ADULT PATIENTS OFFICIALLY INITIATED AT TH
Sep. 15
VOLUNTARY ANNOUNCEMENT - SYS6010 GRANTED BREAKTHROUGH THERAPY DESIGNATION BY NMPA IN CHINA FOR THE TREATMENT OF PATIENTS WITH ACTIONABLE GENOMIC ALTERATION-NEGA
Sep. 14
VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL DATA OF SYS6010 IN COMBINATION WITH ENLONSTOBART FOR THE TREATMENT OF SYSTEMIC TREATMENT-NAIVE, ACTIONABLE GE
Sep. 09
VOLUNTARY ANNOUNCEMENT - GOSERELIN SUSTAINED-RELEASE INJECTION (SYH9102 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us